cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Immediately Placed Dental Implants With Local Application of Injectable PRF in Periodontally Compromised Sites

The present study is a human, prospective, parallel, randomised controlled clinical trial conducted to explore the efficacy of injectable PRF around dental implants. The trial is in accordance with the Consolidated Standards of Reporting Trials (CONSORT) criteria, 2010.

Ten healthy individuals satisfying the inclusion and exclusion criteria were recruited for the study. A detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. All patients were informed about the nature of the study, the surgical procedure involved, potential benefits and risks associated with the surgical procedure and written informed consent were obtained from all patients.

All the patients were treated with immediate implants. The injectable -PRF was coated on implants as well as injected in the socket in both the maxillary and mandibular anterior region. The clinical and radiographic parameters were recorded at baseline, three months and six months postoperatively.

Eligibility Criteria:
Inclusion Criteria:

1. Cooperative patients willing to participate in the study 2. At least two maxillary or mandibular anterior teeth indicated for extraction due to chronic periodontitis (chronic or aggressive) 3. Patients above 18 years of age 4. Patients with esthetic concerns 5. Patients with good oral hygiene maintenance 6. Adequate bone height apical to alveolus of the failing teeth (more than or equal to 5mm) to accommodate an implant

-

Exclusion Criteria:

1. Persistent \& unresolved infection at implant site
2. Teeth with close proximity to anatomical structure and adjacent roots
3. Patients on radiotherapy
4. Patients with systemic disorders
5. Patients with parafunctional habits
6. Patients with history of alcohol, drug dependency and smoking
Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery

The purpose of this study is to record signatures from the fluid surrounding the spinal cord from people who have an implanted drug infusion system.

The purpose of this feasibility study is to record cerebrospinal fluid (CSF) signatures from subjects who have an implanted drug infusion system and who undergo clinical tests designed to troubleshoot possible catheter-related problems as part of their normal standard of care. Signatures will be correlated with physician-determined catheter status.

Eligibility Criteria:
Inclusion Criteria:

* Be at least 12 years of age
* Have an implanted Medtronic drug infusion system for chronic intrathecal administration of drugs
* Report decreased therapeutic benefit, or show visible signs and/or symptoms of decreased therapeutic benefit
* Agree to undergo clinical tests designed to troubleshoot catheter-related problems or failure as a part of their normal standard of care
* Agree to provide signed informed consent.

Exclusion Criteria:

* Are currently enrolled or plan to enroll in another investigational drug or device trial
* Have participated in an investigational drug or device study within 30 days of the in-clinic visit
* Whose health status would, in the opinion of the Clinical Investigator, be jeopardized by participation in the study
Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects

Primary object : Evaluate pharmacokinetic property administered S-pantoprazole 20mg and Pantoprazole 40mg in healthy male subjects

Secondary object : Evaluate safety administered S-pantoprazole 20mg and Pantoprazole 40mg in healthy male subjects


Eligibility Criteria:
Inclusion Criteria:

* Adult healthy males 20 to 45 years at screening.
* BMI : 19kg/m2 \~ 26kg/m2
* Blood Pressure : "140 \> sitting SBP ≥ 90mmHg, 90 \> sitting DBP ≥ 60mmHg"

Exclusion Criteria:

* Have history of significant hepatic, renal, gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
* Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or surgery(except for Appendectomy, Hernia repair) affected the absorption of medications
* Have history of GERD, Gastric ulcer, Duodenal ulcer
* Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of benzimidazole(ex:pantoprazole, NSAID, antibiotic)
* Have a history of drug abuse
* Unusual diet affected the absorption, distribution, metabolism, excretion of medications
* Subject who treated with any investigational drugs within 90 days before the administration of investigational drug
* Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
* Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
* Subject who have taken habitually caffeine (caffeine \> 5 units/day)
* Subject who have drunken habitually (alcohol \> 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
* Subjects deemed ineligible by investigator based on other reasons
Mindfulness-based Prenatal Education on Women

The purpose of this study is to explore the differences between stress, anxiety, depression, mindfulness, mother and infants bonding, salivary amylase activity, and postnatal maternal outcomes for prenatal mental disorders in women with mindfulness prenatal education program

The aim of this study was to test the efficacy of a Mindfulness prenatal education program in reducing pregnant women's perceived stress, anxiety, depression, mindfulness, mother and infant bonding, and salivary alpha-amylase compared to a control group. The investigators hypothesize that using the mindfulness prenatal education program by the study group will lead to improved related mood symptoms compared with the control group.

Randomized Controlled Trial comparing two education programs with health and singleton pregnant women is run by the Random Allocation Software (Saghaei, 2004). Use the G-Power 3.1.9 windows: repeated measures and between factors among two groups to calculate the number of samples, and setting the power = .8, α = .05, effect size = .25. The estimated number of samples may be lost 30%, total 102 samples.

Eligibility Criteria:
Inclusion Criteria:

* Subjects were at the age over 20
* Could speak and read Chinese fluently
* Willing and be ale to attend the education program

Exclusion Criteria:

* Taking medication for diagnosing mental illness
* With complicated or high-risk pregnancies
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.


Eligibility Criteria:
Inclusion Criteria:

Psoriasis vulgaris of both sex, age 18-55 years

Exclusion Criteria:

i. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months
Comparison Between Fixed- Versus Mobile-bearing TKA

The purpose of the study is to analyse the clinical and radiological results of a postero-stabilized TKA by using a mobile bearing versus fixed. Only patients with medial femorotibial arthritis will be included. The consequences on the patellofemoral joint will be thoroughly analysed on skyline view.


Eligibility Criteria:
Inclusion Criteria:

* Medial medial femorotibial arthritis requiring an arthroplasty
* Age between 50y and 90y

Exclusion Criteria:

* Lateral femorotibial arthritis
* Inflammatory disease
* Stiff knee with flexion under 90°
* Revision TKA
* Previous surgery (except meniscectomy)
Effect of Suanzaoren Decoction and Huanglian Wendan Decoction on Biorhythm of Insomnia Patients

The purpose of this study was to examine the impact of Chinese medicine on melatonin levels in patients with insomnia

This was a single-centre, non-randomised, interventional study with a planned enrolment of 20 subjects, including 10 Chinese insomnia patients and 10 healthy subjects. All subjects giving written informed consent. Healthy subjects were admitted to the study ward at baseline (D-3), completed the Pittsburgh Sleep Quality Index (PSQI), Morning and Evening Questionnaire (MEQ), and began saliva collection at 16:00, stayed overnight in the study ward that night and were discharged the following day (D-2). Insomnia patients were admitted to the study ward at baseline (D-3), completed the PSQI and MEQ questionnaires and started saliva collection at 16:00, stayed overnight in the study ward and left the following day (D-2) after completing the relevant examinations. After 4 weeks of treatment with Suanzaoren Decoction and Huanglian Wendan Decoction, the subject was re-admitted to the study ward on D30, completed the PSQI and MEQ questionnaires and started saliva collection at 16:00, stayed overnight in the study ward and left on the following day (D31) after completing the relevant examinations. The intervention for patients with insomnia in this study was the administration of Suanzaoren Decoction and Huanglian Wendan Decoction twice a day for 4 weeks. Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-55, male or female；
* Insomnia patients: patients who met the diagnostic criteria for insomnia in the Chinese Guidelines for the Diagnosis and Treatment of Insomnia in Adults (2017 edition) and who were judged to have moderate-to-severe insomnia according to the Insomnia Severity Index Scale; Healthy subjects: those who had normal sleep, and who met the scores of 0 to 7 on the Insomnia Severity Index Scale;
* Informed consent, voluntary participation in the study；

Exclusion Criteria:

* People with mental illness;
* Chronic insomnia with yang deficiency and yin deficiency, clinical manifestations: coldness of the whole body and hands and feet, like warmth and pressing, yellowish colour, unshaped stools, lumbago, weakness of the legs, nocturia, pale tongue with thin white moss;
* Pregnant, lactating women;
* Have a serious primary heart, liver, lung, kidney, haematological or serious disease affecting their survival, e.g. tumour or AIDS, SCr \> 1.5N (N is the upper limit of normal), ALT \> 2N (N is the upper limit of normal), blood leucocytes \< 3.0 x 109/L;
* Participants in any other clinical trial within 3 months prior to dosing;
* Those who are vulnerable to missing visits based on other circumstances that the researcher judges to be unsuitable for enrolment, such as changes in the work environment.
Reality-monitoring & Stress

Reality-monitoring is a crucial cognitive process in daily life to remember the source of an information. Deficits of reality-monitoring have been shown into the continuum of schizophrenia, suggesting a preexisting alteration in population at-risk for psychosis that will be exacerbated during psychotic transition. It is admitted that stress plays a crucial role in the psychotic transition and can alter cognitive performances. However, less is known about the effects of stress on reality-monitoring, even though this process appears to be central in psychotic disorders.

The aim of this project is to investigate the effect of stress on reality-monitoring, both on behavioral and neurophysiological aspects

Forty healthy subjects will be included in the study. Participants will be subject to a standardized stress protocol, half of them receiving an active stress and the other half receiving a placebo. All participants will also complete a reality-monitoring task, electrophysiological (EEG) recordings as well as socio-demographic and psychometric evaluations

Eligibility Criteria:
Inclusion Criteria:

* Right-handed Men and Women aged between 18 and 30
* Having given their written informed consent
* For women: oral contraceptive use
* French speakers and readers

Exclusion Criteria:

* Do not consent to be included in the study
* Smokers
* Night workers
* Having visual or hearing impairments that could prevent the successful completion of tasks involving reading or listening to sounds
* Taking drug treatment (except oral contraceptive)
* Having a somatic pathology in particular neurological, endocrinal or blood circulation diseases (e.g., Raynaud's disease)
* Having personal or first-degree relatives' history of diagnosed psychiatric disorders (according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - DSM5)
* Having psychotic prodomes measured by a score above 6 in the "prodomal questionnaire' - PQ-16 (Ising et al., 2012)
* Having developed musical abilities (that is, regularly practicing a musical instrument)
* Being pregnant or nursing
Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.

Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .

Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)

Eligibility Criteria:
Inclusion Criteria:

* Patients with idiopathic epilepsy.
* Normal brain imaging (CT brain).
* Patients on anti epileptic drugs more than 6 months.
* No more than two fits per month.
* Score of Mini mental state examination (10-24), mild and moderate cognitive impairment.
* No other medical disorders.

Exclusion Criteria:

* Progressive neurological diseases.
* Abnormal brain imaging (CT brain).
* More than two fits per month.
* Patients with severe cognitive impairment, score of MMSE less than10.
* Patients with severe medical disorders
Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial

Primary insomnia patients will sleep with Quetiapine not better than without Quetiapine

1. Primary insomnia will be diagnosed according to DSM-IV-TR
2. After consenting, cases will be divided (double blind randomization)in to two arms 2.1 sleep hygiene with placebo group 2.2 sleep hygiene with Quetiapine group
3. outcome measurement: sleep diary, sleep satisfaction visual analog scale and sleep satisfaction likert scale
4. statistical method: dependent T test

Eligibility Criteria:
Inclusion Criteria:

* Primary insomnia Patients by DSM-IV-TR criteria
* cases enrolled: age 18-65 educated

Exclusion Criteria:

* Currently receiving Quetiapine or other hypnotic drugs
* Liver disease
* Patients with heart Dz, Hypertension, thyroid disease
* History of epilepsy or febrile convulsion
* pregnant
* cognitive impairments
* History of Orthostatic Hypotension
* Patient with other Psychiatric conditions or Drug dependence
Use of Touch and no Touch Guide-wire Techniques for Deep Biliary Cannulation: the TNT Study

The specific goal of this study is to compare the deep biliary cannulation rate and complication rates associated with use of touch and no touch guide-wire biliary cannulation techniques.

The most common technique used to achieve primary deep biliary cannulation is the standard contrast-assisted method, in which a catheter or sphincterotome is introduced into the papilla in the direction of the bile duct and a contrast medium injected to confirm that the duct has been cannulated.

The biliary guidewire cannulation technique consists of the introduction of a guide-wire into the bile duct instead of contrast injection as the first maneuver.

The benefit of this technique, compared with classic contrast cannulation, has been demonstrated in several studies which show similar results and have been analyzed in a recent meta-analysis, including 5 studies and 1762 patients, and demonstrating that the use of the guide-wire technique significantly improved the primary cannulation rate from 74.9% to 85.3%. More importantly, significantly reduced the incidence of PEP from 8.6% to 1.6%.

There are several variations of this technique; the tip of the sphincterotome is inserted initially a few millimeters through the papillary orifice and then introduce the guide-wire to the target ("touch technique"). Another variation is direct cannulation with the guide-wire hovering a few millimeters through the catheter or sphincterotome ("no touch technique").

To date, there are no randomized controlled trials comparing the two above described way to access to biliary duct regarding efficacy and rate of complications.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Clinical symptoms, laboratory findings and radiological evidences of biliary disease
* Willing and able to comply with the study procedures and provide written informed consent to participate in the study

Exclusion Criteria:

* Age \<18 yars
* Patients with previous sphincterotomy
* Patients with previous papillary endoscopic balloon dilation
* Presence of a previously placed plastic or metal biliary stent
* Presence of any esophageal or gastro/duodenal stent
* Pancreatic or ampullary cancer, proven by imaging and/or cytology and/or histology, are excluded as PEP is very uncommon in these subgroups and tumour-related anatomical variation may alter cannulation technique (consider substratify results for this subgroup, but exclude if duodenal stenosis precludes an attempt on the papilla)
* Patients with surgically altered anatomy (Bilroth II gastrectomy and Roux en Y anastomosis) are excluded as cannulation technique is fundamentally different from that in normal anatomy
* Presence of a diverticular papilla
* Presence of a duodenal stenosis
* Presence of a pancreas divisum
* Patients with contraindication to endoscopic procedures
* Hemodinynamic instability, any acute illness or exacerbation of chronic illness, acute infections.
* Platelet count less than 50,000/mm3 and INR no greater than 1.5 times upper limit of normal
* Inability or refusal to give informed consent.
* Refusal to provide consent
Addition of a Topical Steroid to a Topical Retinoid in Acne Patients

A randomized, split-face, placebo-controlled, double-blind, single-center clinical trial comparing topical retinoid on half the face and retinoid plus topical steroid on the other half.

A randomized, split-face, placebo-controlled, double-blind, single-center clinical trial wherein 20 patients received daily 0.05% tretinoin with one half of the face receiving triamcinolone 0.025% and the other half an inert emollient for 4 weeks. Subjects continued applying tretinoin 0.05% daily to the bilateral face without triamcinolone or emollient for an additional 4 weeks. Investigator's Global Assessment, lesion counts, and study subject's self-assessments of burning/stinging, itching, erythema, and dryness/scaling will be collected at 1, 2, 4, and 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Fitzpatrick skin types I, II, or III
* Will and ability to discontinue use of topical medicines on the face for study duration
* Capability to understand and provide informed consent

Exclusion Criteria:

* Use of oral retinoids within previous 6 months
* Use of corticosteroids on the face or systemic corticosteroids within previous 4 weeks
* Any additional facial skin condition (i.e., rosacea, seborrheic dermatitis, etc.)
* Female participants who are pregnant, nursing, or planning pregnancy while participating in the study
* Hypersensitivity to ingredients in study formulations
* Existence of an underlying condition that an investigator feels would hinder a participant's ability to complete the study or appropriately follow directions
Hand Dynamometer and Clinical Tests to Evaluate Neuromuscular Recovery in Atracurium vs Rocuronium

One of the common serious complications in the postoperative phase is Residual the neuromuscular blockade that confused the anesthesia medical team also patients may become uncomfortable, un ability to clear secretion, un-explanation of decreasing SPO2, increase respiratory effort and lead to an increase in the risk of respiratory complication. Most clinicians used clinical assessment to evaluate neuromuscular recovery such as a head lift for 5 seconds, Sustain leg lift, Tongue protrusion, teeth clenching, swallowing, Tidal volume 5 mL/kg, Handgrips Sustained for 5 seconds, and other clinical assessments in patients undergoing general anesthesia. A few studies have been discussing the utilization of hand dynamometers in the assessment of post-residual neuromuscular block. Our aim is to examine the neuromuscular recovery using a hand dynamometer after receiving Atracurium versus Rocuronium.


Eligibility Criteria:
Inclusion Criteria:

* all patient between 18-60 years old with ASAII under general anesthesia

Exclusion Criteria:

* all patient under 18 years old and over 60 years old
* prior administration of suxamethonium
* patient received magnesium, lithium, Quinidine, calcium channel blockers, local anesthesia
Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia.

Neurocognitive deficits in schizophrenia patients appears to explain up to 61% of the variance of functional outcome and is an important predictor of social reintegration (Peuskens et al, 2005) and independent living activitiy (Green et al, 2004). Impaired social functioning within schizophrenia population has been associated with increased health-care costs. Since social and occupational disability may generate the largest indirect costs of the illness, treatment of cognitive deficits has an enormous impact on the cost and disability associated with schizophrenia (McGurk and Mueser, 2004).

However, the gap between cognitive science and clinical practice limits the implementation of cognitive assessment in the routine evaluation of schizophrenia patients. Pharmaceutical industry initiated numerous large scale, multisite studies on the impact of novel antipsychotics on cognitive deficits in schizophrenia patients.

The aim of this research is to develop population norms of the computerized neuropsychological assessment for effectiveness of the antipsychotic treatment in schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* An IQ, which is within normal range.

Exclusion Criteria:

* Psychiatric co-morbidity.
* Physical disability or illness.
* A history of severe head injury.